Comparison 2. Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly versus sham for geographic atrophy (GA).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 BCVA change at 1 year	3	1184	Mean Difference (IV, Random, 95% CI)	0.22 [‐1.00, 1.44]
2.2 GA lesion size change at 1 year (mm2)	3	1207	Mean Difference (IV, Random, 95% CI)	0.07 [‐0.05, 0.19]
2.3 Safety: Development of MNV or exudative AMD at 1 year	2	1331	Risk Ratio (M‐H, Random, 95% CI)	1.70 [0.67, 4.28]
2.4 Safety: Development of endophthalmitis at 1 year	2	1331	Risk Ratio (M‐H, Random, 95% CI)	4.94 [0.24, 102.78]